Medical Policy

Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis

Table of Contents
- Policy: Commercial
- Coding Information
- Information Pertaining to All Policies
- Policy: Medicare
- Description
- References
- Authorization Information
- Policy History

Policy Number: 677
BCBSA Reference Number: 2.04.119
NCD/LCD: N/A
Local Coverage Article: MolDX: Vectra™ DA Coding and Billing Guidelines (A53110)

Related Policies
None

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

The use of a multi-biomarker disease activity score for rheumatoid arthritis (eg, Vectra® DA score) is considered INVESTIGATIONAL in all situations.

Medicare HMO BlueSM and Medicare PPO BlueSM Members

Medical necessity criteria and coding guidance for Medicare Advantage members living in Massachusetts can be found through the link(s) below.

Local Coverage Determination (LCDs) for Palmetto GBA on Molecular Diagnostic Tests

Local Coverage Article: MolDX: Vectra™ DA Coding and Billing Guidelines (A53110)

Note: To review the specific LCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

For medical necessity criteria and coding guidance for Medicare Advantage members living outside of Massachusetts, please see the Centers for Medicare and Medicaid Services website at https://www.cms.gov for information regarding your specific jurisdiction.
Prior Authorization Information

Inpatient
- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient
- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

<table>
<thead>
<tr>
<th>Commercial Managed Care (HMO and POS)</th>
<th>This is <strong>not</strong> a covered service.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>This is <strong>not</strong> a covered service.</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
</tbody>
</table>

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following CPT codes are considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity**:

CPT Codes

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81490</td>
<td>Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score</td>
</tr>
</tbody>
</table>

Description

**Rheumatoid Arthritis**

RA is characterized by chronic joint inflammation leading to painful symptoms, progressive joint destruction, and loss of function. The disorder is relatively common and associated with a high burden of morbidity for affected patients.

Treatment

Treatment of RA has undergone a shift from symptom management to a more proactive strategy of minimizing disease activity and delaying disease progression. The goal of treatment is to reduce the irreversible joint damage that occurs from ongoing joint inflammation and synovitis by keeping disease activity as low as possible. The availability of an increasing number of effective disease-modifying antirheumatic drugs has made the achievement of remission, or sustained low disease activity, a feasible goal for a large proportion of patients with RA. This treatment strategy has been called a **tight control** approach.

The concept of tight control in the management of RA has gained wide acceptance. Evidence from clinical trials has demonstrated that outcomes are improved with a tight control strategy, in which treatment targets are mainly based on measures of disease activity. In a systematic review, Schoelset et al (2010) identified 7 studies that evaluated the efficacy of tight control. Four of these trials randomized patients to tight control using treatment targets or to routine management, two studies compared different treatment targets, and one study compared results from targeted treatment with historical controls. The treatment targets were heterogeneous, including
symptom-based measures, joint scores on the exam, validated treatment activity measures, lab values, or combinations of these factors. In all 4 trials that randomized patients to tight control or routine management, there was a significant decrease in the Disease Activity Score (DAS) or its 28 joints version (DAS28) and in the likelihood of achieving remission for patients in the tight control group.

According to the American College of Rheumatology (ACR) guidelines, initial treatment of patients with RA is monotherapy (usually a disease-modifying antirheumatic drug). Treatment may progress to combination therapy if disease activity remains moderate or high despite monotherapy. Combination therapy may consist of additional disease-modifying antirheumatic drugs or the addition of tumor necrosis factors or non-tumor necrosis factors biologics.

**Validated Disease Activity Assessment Tools**
For a strategy of tight control to be successful, reliable and valid measurement of disease activity is necessary. There are numerous disease activity measurements that can be used in clinical care.

Through a 5-stage process that included review by an expert advisory panel in RA disease activity and detailed evaluation of psychometric properties, an ACR working group determined that 6 measures were accurate reflections of disease activity: Clinical Disease Activity Index (CDAI), DAS28, Patient Activity Scale, Patient Activity Scale II, Routine Assessment of Patient Index Data 3, and the Simplified Disease Activity Index (SDAI).

Two systematic reviews were published the same year as the ACR's recommendations, one by Gaujoux-Viala et al (2012) and the other by Salaffi et al (2012), which compared disease activity measures for patients with RA. Results from the systematic reviews were consistent with the ACR working group recommendations, citing the DAS28, SDAI, and CDAI as appropriate disease activity measures for RA.

Table 1 summarizes the clinical and laboratory measurements included in each of the six disease activity measures recommended by ACR. The table also includes the laboratory measures included in the Vectra DA, a multibiomarker disease activity test which currently does not have a recommendation from the ACR.

### Table 1. Clinical and Laboratory Components of Rheumatoid Arthritis Disease Activity Measurements

<table>
<thead>
<tr>
<th>Recommended by ACR</th>
<th>No ACR Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28</td>
<td>CDAI and SDAI</td>
</tr>
</tbody>
</table>
| No. of swollen joints out of 28<sup>a</sup> | No. of swollen joints out of 28<sup>a</sup> | Patient describes ability to do each of 20 activities<sup>b</sup> as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 10 activities<sup>c</sup> as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 13 activities<sup>d</sup> as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | • Interleukin-6  
• Tumor necrosis factor receptor type I  
• Vascular cell adhesion molecule 1  
• Epidermal growth factor  
• Vascular endothelial growth factor A |
<p>| PAS                | Patient describes ability to do each of 20 activities&lt;sup&gt;b&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 10 activities&lt;sup&gt;c&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 13 activities&lt;sup&gt;d&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | | |
| PAS II             | Patient describes ability to do each of 20 activities&lt;sup&gt;b&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 10 activities&lt;sup&gt;c&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 13 activities&lt;sup&gt;d&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | | |
| RAPID3            | Patient describes ability to do each of 20 activities&lt;sup&gt;b&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 10 activities&lt;sup&gt;c&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | Patient describes ability to do each of 13 activities&lt;sup&gt;d&lt;/sup&gt; as “without any difficulty,” “with some difficulty,” “with much difficulty,” or “unable to do” | | |</p>
<table>
<thead>
<tr>
<th>No. of tender joints out of 28&lt;sup&gt;a&lt;/sup&gt;</th>
<th>No. of tender joints out of 28&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Patient indicates need for cane, crutches, walker, wheelchair, or devices to assist with dressing or eating</th>
<th>Patient rates pain on scale of 0 (no pain) to 10 (severe pain)</th>
<th>Patient rates pain on scale of 0 (no pain) to 10 (severe pain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR (mm/h)</td>
<td>CRP (mg/L)</td>
<td>Patient indicates need for assistance in dressing, rising, eating, walking, hygiene, reaching, gripping, or chores</td>
<td>Patient rates how they are doing on scale of 0 (very well) to 10 (very poor)</td>
<td>Patient rates how they are doing on scale of 0 (very well) to 10 (very poor)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>Patient Global Assessment (0 [very well] to 10 [very poor])</td>
<td>Patient indicates if special devices needed in bathroom or kitchen</td>
<td>Patient indicates if special devices needed in bathroom or kitchen</td>
<td>Patient indicates if special devices needed in bathroom or kitchen</td>
</tr>
<tr>
<td>Patient Global Assessment (0 [best] to 100 [worst])</td>
<td>Physician Global Assessment (0 [very well] to 10 [very poor])</td>
<td>Patient rates pain on scale of 0 (no pain) to 10 (severe pain)</td>
<td>Patient rates pain on scale of 0 (no pain) to 10 (severe pain)</td>
<td>Patient rates pain on scale of 0 (no pain) to 10 (severe pain)</td>
</tr>
<tr>
<td>Patient rates how they are doing on scale of 0</td>
<td>Patient ratings how they are doing on scale of 0</td>
<td>Patient rates how they are doing on scale of 0</td>
<td>Patient rates how they are doing on scale of 0</td>
<td>Patient rates how they are doing on scale of 0</td>
</tr>
</tbody>
</table>

- YKL-40 glycoprotein
- MMP-1
- MMP-3
- C-reactive protein
- Serum amyloid A
- Leptin
- Resistin
Adapted by Anderson et al (2012). ACR: American College of Rheumatology; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; MMP: matrix metalloproteinase; PAS: Patient Activity Scale; RAPID3: Routine Assessment of Patient Index Data 3; SDAI: Simplified Disease Activity Index.
a Twenty-eight joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees.
b Dress self; shampoo hair; stand from chair; get in and out of bed; cut meat; bring cup to mouth; open milk carton; walk outdoors on flat ground; climb 5 steps; wash and dry body; take tub bath; get on and off toilet; reach and bring down 5 pound object from above head; bend and pick up clothing from floor; open car door; open new jar; turn faucets on and off; run errands; get in and out of car; do chores (eg, vacuum or yard work).
c Stand from chair; walk outdoors on flat ground; get on and off toilet; reach and bring down 5 pound object from above head; open car door; do outside work such as yard work; wait in line for 15 minutes; lift heavy objects; move heavy objects; climb 2 or more flights of stairs.
d Dress self; get in and out of bed; bring cup to mouth; walk outdoors on flat ground; wash and dry body; bend and pick up clothing from floor; turn faucets on and off; get in and out of car; walk 2 miles; participate in recreational activities; sleep well; deal with feelings of anxiety or nervousness; deal with feelings of depression or sadness.

**Vectra DA Test**
The manufacturer describes Vectra DA as a complement to clinical judgment. Although not explicitly stated, it appears that the test may be used as an adjunct to other disease activity measures, to potentially identify patients at high-risk of progression who would, therefore, benefit from a more aggressive treatment strategy.

The Vectra DA test scores range from 1 to 100. Categories of scores were constructed to correlate with the DAS28-CRP scale:

- 45-100: high disease activity
- 30-44: moderate disease activity
- 1-29: low disease activity.

**Summary**
Assessment of disease activity in rheumatoid arthritis is an important component of management with a goal of treatment to maintain low disease activity or achieve remission. There are a variety of instruments for measuring rheumatoid arthritis disease activity. The instruments use combinations of physical exam findings, radiologic results, and serum biomarkers to construct a disease activity score. A multibiomarker disease activity instrument is a disease activity measure that is comprised entirely of serum biomarkers. The Vectra DA test is a commercially available multibiomarker disease activity blood test that uses 12 biomarkers to construct a disease activity score ranging from 1 (low disease activity) to 100 (high disease activity).

For individuals who have rheumatoid arthritis who receive a multibiomarker disease activity (eg, Vectra DA) test as an adjunct or as a replacement of other disease activity measures, the evidence includes analyses of archived serum samples from randomized controlled trials and prospective cohort studies. The relevant outcomes are test validity, other test performance measures, symptoms, change in disease status, functional outcomes, and quality of life. Analyses comparing Vectra DA with other previously validated disease activity measures such as the Disease Activity Score with 28 joints or to radiographic progression, consisted mostly of correlations, with only 1 study providing sensitivity, specificity, and positive and negative predictive values. The positive predictive value from this study was 21%. Other analyses of archived serum samples evaluated the use of Vectra DA to predict treatment...
response. Results from those analyses were inconsistent. The body of evidence on the Vectra DA test is insufficient to determine whether it is as good as or better than other disease activity measures. Additionally, there is no evidence evaluating Vectra DA as an adjunct to other disease activity measures. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>7/2016</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>1/2016</td>
<td>Clarified coding information.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:
- [Medical Policy Terms of Use](#)
- [Managed Care Guidelines](#)
- [Indemnity/PPO Guidelines](#)
- [Clinical Exception Process](#)
- [Medical Technology Assessment Guidelines](#)

**References**


27. Palmetto GBA. Vectra DA Coding and Billing Guidelines (M00031, V10).